Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Teva's Opioid Options Come Into More Focus Ahead Of Third Quarter Financials

Investors may have more clarity on Teva's long-term outlook if the generic drug maker reaches a settlement in a big opioid case before it goes to trial in Ohio next week.

Legal Issues Generic Drugs Sales & Earnings

AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing

AstraZeneca, which analysts said had an 'exceptional' second quarter, is expected to have also kept that momentum up in the third quarter.
Sales & Earnings Companies Cancer

Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived

Genfit believes elafibranor’s clean tolerability and safety profile may help narrow the gap between it and Intercept’s OCA, with safety questions delaying OCA’s entry to market. Part two of Scrip’s interview with Genfit’s CEO and COO.

Business Strategies Clinical Trials Research and Development Strategies

Spotlight On APAC

'Buy China' In Procurement Schemes - Should You Worry?

A recent trade group report points to a rising and alarming "Buy China" trend in procurement rounds in the country. Although largely in medical device bidding, it may potentially affect the pharma sector, an analysis from the recent “4+7” centralized bidding scheme show.

China Commercial

Advertisement


 Recent Tweets from Scrip


Advertisement

 

Commercial Explore this Topic

Set Alert for Commercial

Roche Expects Better Xofluza Sales After New Indication

Flu treatment is newly approved for patients at higher risk of flu complications, and Roche is studying other patient groups that could help expand its potential market.      
Approvals Advertising, Marketing & Sales

Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy

The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.

Deals Research and Development Strategies

Sofinnova Raises €333m For European Biotech Fund

Global investors back Paris-headquartered Sofinnova to recoup investment in life science start-ups.
Europe Commercial

Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?

Industry would settle for UK Prime Minister Boris Johnson’s deal, with sweeteners promised for the sector.
United Kingdom Commercial

Novartis Q3 Preview: Zolgensma Back In The Spotlight

Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.

Sales & Earnings Commercial

Need For Partnering Won’t Change But Shape Might - BioJapan

While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.

Asia Pacific Research and Development Strategies
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Kiadis Crushed By EMA Rejection Of T-Cell Therapy

The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.
Clinical Trials Drug Review

Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?

Industry would settle for UK Prime Minister Boris Johnson’s deal, with sweeteners promised for the sector.
United Kingdom Commercial

Shake It Off? Japan Mulls Routes Out Of Bioventure Doldrums

The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.

Japan Gene Therapy
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Evenity Gets CHMP Nod On Second Pass

UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.

Approvals Europe

Lilly’s Pegilodecakin Fails Pancreatic Cancer Test

The company's immunotherapy failed to improve survival of pancreatic patients compared to chemotherapy. Lilly will be hoping pegilodecakin has more success in NSCLC.

Clinical Trials ImmunoOncology

Lilly Calls Time On UK Neuroscience Research Center

The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.

United Kingdom Companies
See All
UsernamePublicRestriction

Register

Advertisement